Content deleted Content added
Vaccinationist (talk | contribs) mNo edit summary |
m Infobox drug: rm/replace dedeprecated params. Fix unk parameters (via AWB script) |
||
Line 5: | Line 5: | ||
| image = Balsalazide structure.svg |
| image = Balsalazide structure.svg |
||
| width = 270 |
| width = 270 |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Colazal, Giazo |
| tradename = Colazal, Giazo |
||
Line 14: | Line 13: | ||
| legal_UK = POM |
| legal_UK = POM |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = <1% |
| bioavailability = <1% |
||
Line 20: | Line 18: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = 12hr |
| elimination_half-life = 12hr |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 80573-04-2 |
| CAS_number = 80573-04-2 |
||
Line 30: | Line 26: | ||
| PubChem = 5362070 |
| PubChem = 5362070 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = DB01014 |
|||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 10662422 |
| ChemSpiderID = 10662422 |
||
Line 39: | Line 35: | ||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = 1201346 |
| ChEMBL = 1201346 |
||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=17 | H=15 |
| C=17 | H=15 |
||
| N=3 | O=6 |
|||
| molecular_weight = 357.318 g/mol |
| molecular_weight = 357.318 g/mol |
||
| smiles = O=C(O)c1cc(ccc1O)/N=N/c2ccc(cc2)C(=O)NCCC(O)=O |
| smiles = O=C(O)c1cc(ccc1O)/N=N/c2ccc(cc2)C(=O)NCCC(O)=O |
Revision as of 12:53, 27 June 2015
Clinical data | |
---|---|
Trade names | Colazal, Giazo |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699052 |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | <1% |
Protein binding | ≥99% |
Elimination half-life | 12hr |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.117.186 |
Chemical and physical data | |
Formula | C17H15N3O6 |
Molar mass | 357.318 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers.
It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA,[1] in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
Synthesis
- Starting material is 4-aminohippuric acid, obtained by coupling para-aminobenzoic acid and glycine.
- That product is then treated with nitrous acid to give the diazonium salt.
- Reaction of this species with salicylic acid proceeds at the position para to the phenol to give balsalazide.
References
- ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11709512, please use {{cite journal}} with
|pmid=11709512
instead.